TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Nykode Therapeutics ASA
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
8,416
|
12,736
|
7,578 |
| Financial expenses |
5,994
|
4,618
|
6,834 |
| Earnings before taxes |
-44,132
|
-43,519
|
-53,898 |
| Total assets |
148,823
|
205,507
|
234,141 |
| Current assets |
113,513
|
163,544
|
223,988 |
| Current liabilities |
8,823
|
20,343
|
41,214 |
| Equity capital |
132,080
|
169,056
|
165,996 |
| - share capital |
356
|
362
|
357 |
| Employees (average) | 139 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
88.7%
|
82.3%
|
70.9% |
| Turnover per employee | 61 | ||
| Profit as a percentage of turnover |
-524.4%
|
-341.7%
|
-711.2% |
| Return on assets (ROA) |
-25.6%
|
-18.9%
|
-20.1% |
| Current ratio |
1286.6%
|
803.9%
|
543.5% |
| Return on equity (ROE) |
-33.4%
|
-25.7%
|
-32.5% |
| Change turnover |
-4,095
|
5,660
|
-28,327 |
| Change turnover % |
-33%
|
80%
|
-79% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.